Treatment of chronic hepatitis C with PegIFN-alfa2b and ribavirin within a large German multicentric observational study: response to therapy depends on patients' age
D Hüppe, E Zehnter, MP Manns, G Teuber, T Dahhan, S Kaiser, U Meyer, T Witthöfft, B Möller, N Dikopoulos, J Brack, M Bilzer, G Tossing, S Mauss · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: The current treatment of choice for hepatitis C is a combination of pegylated interferon-alfa (PegIFN-alfa) plus ribavirin. No age dependency of SVR has been described recently from the WIN-R cohort comparing patients older than 65 (SVR=46%) with those younger than 65 years (SVR=46%). A subgroup of patients between 18 to 25 years experienced higher SVR-rates of 57%. We evaluated the correlation of age and SVR within age decades 20 to 30 (group I), 30 to 40 (group II), 40 to 50 (group III), 50 to 60 (group IV) and 60 to 70 (group V) years, respectively. Methods: Between 2003 and 2009, 279 sites treated a to…
